title: The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.
abstract: Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.
authors.affiliation: Department of Medicine, Royal Marsden Hospital, London, U.K.
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.forename: E
authors.initials: E
authors.lastname: Galligioni
authors.forename: C W
authors.initials: CW
authors.lastname: Keen
authors.forename: R
authors.initials: R
authors.lastname: Sorio
authors.forename: E M
authors.initials: EM
authors.lastname: Loriaux
authors.forename: H C
authors.initials: HC
authors.lastname: Grobben
authors.forename: C R
authors.initials: CR
authors.lastname: Franks
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins